All News
Filter News
Found 809,159 articles
-
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
3/10/2022
Progenity, Inc., an innovative biotechnology company, announced progress with its clinical device performance study plan, evaluating the device function and safety of its Drug Delivery System capsule.
-
Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022
3/10/2022
Cognition Therapeutics will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer’s disease and other neurodegenerative disorders.
-
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
3/10/2022
AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily (QD) and 30 mg twice daily (BID) doses, across the 12-week treatment period.
-
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
3/10/2022
Ceapro Inc. announced the signing of a long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.
-
Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results
3/10/2022
Applied Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Emerging Technology Insider Releases a New TechTalks Video Interview Featuring Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc.
3/10/2022
Emerging Technology Insider announced a new TechTalks video featuring an interview with Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc..
-
Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis
3/10/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today reported positive clinical data from its recently completed Phase 1 clinical trial evaluating the safety and tolerability of PIPE-307 in healthy volunteers.
-
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
3/10/2022
Sensei Biotherapeutics, Inc. today reported financial results for 2021 and provided recent corporate updates.
-
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
3/10/2022
SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the intended formation of a joint venture ("JV") to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions.
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
3/10/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2021, announced plans to conduct interim analyses of its OraGrowtH210 and OraGrowtH212 Trials, and provided an update on clinical activities and financial guidance for 2022.
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
3/10/2022
Dyne Therapeutics, Inc. today reported financial results for the fourth quarter and full year 2021 and recent business highlights.
-
Zealand Pharma convenes its Annual General Meeting 2022
3/10/2022
Zealand Pharma A/S convenes the Annual General Meeting of the Company to be held on Wednesday April 6, 2022 at 3:00pm.
-
Inari Medical Announces Proposed Offering of Common Stock
3/10/2022
Inari Medical, Inc. today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock.
-
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
3/10/2022
Zealand Pharma:Significant Advancement of Clinical Pipeline and Building Commercial Momentum.
-
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
3/10/2022
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has entered into an agreement with KBI Biopharma, Inc. (“KBI”) for the process transfer, process optimization and cGMP manufacturing of the Company’s intranasal vaccine candidate NT-CoV2-1.
-
Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology Target
3/10/2022
Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target.
-
Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution™ Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction
3/10/2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), today announced that it has signed an agreement with Cervos Inc. ("Cervos Medical") to become the exclusive distributor of Marrow Cellution™ devices for use in urology, gynecology, and male and female sexual dysfunction.
-
Sierra Oncology Reports 2021 Year End Results
3/10/2022
Sierra Oncology, Inc. today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021.
-
Announcing New Fourier 80 Benchtop FT-NMR Capabilities for Pharmaceutical and Food Analysis Markets
3/10/2022
Bruker Corporation announces new capabilities for its benchtop Fourier transform nuclear magnetic resonance spectrometer, the Fourier 80, which does not require special lab infrastructure or cryogens, and offers excellent 1H sensitivity of 200:1 for gradient spectroscopy proton probes.
-
Gemini Therapeutics Reports 2021 Financial Results
3/10/2022
Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.